Use of Nanoparticles in Delivery of Nucleic Acids for Melanoma Treatment

Obeid, Mohammad A.; Aljabali, Alaa A. A.; Rezigue, Meriem; Amawi, Haneen; Alyamani, Hanin; Abdeljaber, Shatha N; Ferro, Valerie A.

doi:10.1007/978-1-0716-1205-7_41

Cited by 13 publications

(9 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The technologies for reversing tumor MDR at the gene level mainly include antisense nucleic acid technology, 413 ribozyme technology, 414 and RNA interference (RNAi) technology 415,416 . Drugs that regulate miRNA expression (such as miR‐125, −20, −24) may have specific clinical application prospects in reversing tumor MDR 417,418 .…”

Section: Perspectives In Overcoming Cancer Resistancementioning

confidence: 99%

Understanding and targeting resistance mechanisms in cancer

Lei

Teng

Wurpel

et al. 2023

MedComm

View full text Add to dashboard Cite

Resistance to cancer therapies has been a commonly observed phenomenon in clinical practice, which is one of the major causes of treatment failure and poor patient survival. The reduced responsiveness of cancer cells is a multifaceted phenomenon that can arise from genetic, epigenetic, and microenvironmental factors. Various mechanisms have been discovered and extensively studied, including drug inactivation, reduced intracellular drug accumulation by reduced uptake or increased efflux, drug target alteration, activation of compensatory pathways for cell survival, regulation of DNA repair and cell death, tumor plasticity, and the regulation from tumor microenvironments (TMEs). To overcome cancer resistance, a variety of strategies have been proposed, which are designed to enhance the effectiveness of cancer treatment or reduce drug resistance. These include identifying biomarkers that can predict drug response and resistance, identifying new targets, developing new targeted drugs, combination therapies targeting multiple signaling pathways, and modulating the TME. The present article focuses on the different mechanisms of drug resistance in cancer and the corresponding tackling approaches with recent updates. Perspectives on polytherapy targeting multiple resistance mechanisms, novel nanoparticle delivery systems, and advanced drug design tools for overcoming resistance are also reviewed.

show abstract

Section: Perspectives In Overcoming Cancer Resistancementioning

confidence: 99%

Understanding and targeting resistance mechanisms in cancer

Lei

Teng

Wurpel

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…Conducted clinical trials in South Africa by Novavax and Johnson & Johnson discussed the comparable effectiveness of their new vaccines against the high prevalence of E484K mutant virus. Novavax reported a 60% efficacy compared with 86% in the UK [ 36 , 48 ]. The Nigerian variant’s genome is very similar to the Kent variant, B.1.1.7, and its spike protein carries the E484K mutation, similar to the South African and Brazilian variants.…”

Section: Nanoparticles and Novel Covid-19 Mrna Vaccine Developmentmentioning

confidence: 99%

SARS-CoV-2: Vaccinology and Emerging therapeutics; Challenges and Future Developments

Adesokan¹,

Obeid

Lawal³

2022

Ther. Deliv.

Self Cite

View full text Add to dashboard Cite

As SARS-CoV-2 emerge, variants such as Omicron (B.1.1.529), Delta (B.1.617.2), and those from the United Kingdom (B.1.1.7), South Africa (B.1.351), Brazil (P.1) and India (B.1.6.17 lineage) have raised concerns of the reduced neutralising ability of antibodies and increased ability to evade the current six approved COVID-19 vaccine candidates. This viewpoint advocates for countries to conduct prior efficacy studies before they embark on mass vaccination and addresses the role of nanoparticles as carrier vehicles for these vaccines with a view to explore the present challenges and forge a path for a stronger and more viable future for the development of vaccines for SARS-CoV-2 and future pandemics. We also look at the emerging prophylactics and therapeutics in the light of ongoing cases of severe and critical COVID-19.

show abstract

“…In this manner, the researchers obtained a consistent range of particle sizes, with dimensions below 100 nm, narrow size distribution, spherical shape, good stability, and high encapsulation efficiencies. In what concerns their applicability, numerous lipid-based TNA delivery platforms have been recently constructed as potent novel platforms for cancer immunotherapies [35]. In particular, the use of mRNA formulations for different types of solid tumors and hematological malignancies is currently examined by various studies and even clinical trials [28].…”

Section: Lipid-based Delivery Systemsmentioning

confidence: 99%

“…Clinical trials demonstrated the efficacy of LNP-mRNA formulations and an acceptable safety profile, leading to their approval for mass immunization [58,59]. In what concerns their applicability, numerous lipid-based TNA delivery platforms have been recently constructed as potent novel platforms for cancer immunotherapies [35]. In particular, the use of mRNA formulations for different types of solid tumors and hematological malignancies is currently examined by various studies and even clinical trials [28].…”

Section: Lipid-based Delivery Systemsmentioning

confidence: 99%

New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery

2021

View full text Add to dashboard Cite

Nucleic acids represent a promising lead for engineering the immune system. However, naked DNA, mRNA, siRNA, and other nucleic acids are prone to enzymatic degradation and face challenges crossing the cell membrane. Therefore, increasing research has been recently focused on developing novel delivery systems that are able to overcome these drawbacks. Particular attention has been drawn to designing lipid and polymer-based nanoparticles that protect nucleic acids and ensure their targeted delivery, controlled release, and enhanced cellular uptake. In this respect, this review aims to present the recent advances in the field, highlighting the possibility of using these nanosystems for therapeutic and prophylactic purposes towards combatting a broad range of infectious, chronic, and genetic disorders.

show abstract

Use of Nanoparticles in Delivery of Nucleic Acids for Melanoma Treatment

Cited by 13 publications

References 157 publications

Understanding and targeting resistance mechanisms in cancer

Understanding and targeting resistance mechanisms in cancer

SARS-CoV-2: Vaccinology and Emerging therapeutics; Challenges and Future Developments

New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery

Contact Info

Product

Resources

About